Disc Medicine (IRON) said Monday that it presented data supporting the advancement of its three investigational drugs.

The company said phase 2 studies showed that its drug candidate bitopertin reduces protoporphyrin IX levels and improves symptoms in adults and adolescents with erythropoietic protoporphyria, a genetic condition that can lead to liver disease.

Updates from pre-clinical studies showed a combination of ruxolitinib with DISC-0974's mouse analog showed potential as a treatment for anemia in myelofibrosis and inflammatory bowel disease, according to the company.

The company also said that DISC-3405 reduced serum iron levels and was well-tolerated in healthy volunteers, suggesting potential for treating polycythemia vera and sickle cell disease.

Shares of the company were down 1.5% in recent trading.

Price: 63.88, Change: -0.94, Percent Change: -1.45